To read the full story
Related Article
- Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
- Gilead Files HIV Med Lenacapavir in Japan
June 5, 2023
BUSINESS
- ViiV’s Vocabria-Rekambys Combo Nets 50% Growth: Japan President
September 11, 2024
- Axcelead DDP, Acadia to Join Forces in Drug Discovery
September 11, 2024
- KM Biologics Bags Option to Osivax’s Universal Flu Vaccines
September 11, 2024
- Kissei, Reborna Form Research Tie-Up for Genetic Rare Diseases
September 10, 2024
- Healios, FDA Agree on Pivotal PIII Design for Cell Therapy MultiStem
September 10, 2024
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…